Therefore, pharmacological and genetic inhibition of the PI3K/AKT signaling pathway has been demonstrated to attenuate RCC migration and invasion, highlighting its therapeutic relevance, such as PI3K inhibitor treatment reduces RCC progression (Khalid et al., 2023). This evidence concerns the gene AKT1 and renal cell adenocarcinoma.